Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Common Equity: 2017-2024

Historic Common Equity for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $485.0 million.

  • Arcus Biosciences' Common Equity fell 22.83% to $436.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $436.0 million, marking a year-over-year decrease of 22.83%. This contributed to the annual value of $485.0 million for FY2024, which is 4.98% up from last year.
  • Latest data reveals that Arcus Biosciences reported Common Equity of $485.0 million as of FY2024, which was up 4.98% from $462.0 million recorded in FY2023.
  • Arcus Biosciences' 5-year Common Equity high stood at $842.0 million for FY2021, and its period low was $462.0 million during FY2023.
  • For the 3-year period, Arcus Biosciences' Common Equity averaged around $534.7 million, with its median value being $485.0 million (2024).
  • Per our database at Business Quant, Arcus Biosciences' Common Equity surged by 206.58% in 2020 and then decreased by 29.68% in 2023.
  • Over the past 5 years, Arcus Biosciences' Common Equity (Yearly) stood at $502.3 million in 2020, then skyrocketed by 67.63% to $842.0 million in 2021, then declined by 21.97% to $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then increased by 4.98% to $485.0 million in 2024.